secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001437749-24-035331
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q1 revenue $13.6M (+5.4% YoY); net income $0.3M vs loss
----------------------------------------------------------------------------

- Revenue $13.6M versus $12.9M YoY; operating income $0.5M versus operating loss of $54K.
- Net income $259K ($0.01 diluted EPS) compared to net loss of $59K ($0.00) in prior year.
- Two largest customers represented 85% of revenue (down from 91%), reflecting diversification.
- No forward guidance or dividend changes were provided in the release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774924035331/0001437749-24-035331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774924035331/inbp20241112_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-035331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer